## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.5% below STRENGTH zone (3.0-6.0%); PEG 1.25 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($462.51)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. HCA Healthcare Stock: Quiet Rally, Firm Guidance, And A Market Still Deciding What Comes Next**
- Source: AD HOC NEWS | 20260105T015225 | Bullish | Relevance: 100%
- HCA Healthcare's stock has shown a quiet but steady rally, driven by strong fundamentals, consistent guidance, and a focus on returning cash to shareholders. Despite market attention on tech giants, HCA has posted solid gains by offering predictable cash flow and demonstrating resilience against industry headwinds. Wall Street analysts largely maintain a constructive view, seeing continued upside for the defensive leader.

**2. Truist Financial Increases HCA Healthcare (NYSE:HCA) Price Target to $520.00**
- Source: MarketBeat | 20260106T145405 | Bullish | Relevance: 100%
- Truist Financial has raised its price target for HCA Healthcare (NYSE:HCA) from $495.00 to $520.00, maintaining a "buy" rating, indicating an 8.44% potential upside. This adjustment follows HCA's strong quarterly performance, which beat EPS and revenue estimates and set optimistic FY2025 guidance. The consensus among analysts is a "Moderate Buy" for HCA, with an average target price of $480.32.

**3. Gateway Investment Advisers LLC Lowers Stake in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20260104T122818 | Bullish | Relevance: 100%
- Gateway Investment Advisers LLC decreased its stake in HCA Healthcare by 6.4% in the third quarter of 2025 by selling 5,610 shares, leaving it with 81,974 shares valued at $34.94 million. This reduction comes as HCA Healthcare reported strong Q3 earnings, beating estimates, and analysts have raised price targets, giving the stock a "Moderate Buy" consensus. An EVP also significantly reduced his holdings, while other institutional investors have bought shares.

**4. Outpatient Clinics Market Is Going to Boom | HCA Healthcare, Ascension Health, Kaiser Permanente, Mayo Clinic**
- Source: openPR.com | 20260106T120809 | Bullish | Relevance: 95%
- The Outpatient Clinics Market is projected to grow from USD 102.81 billion in 2025 to USD 150.55 billion by 2032, exhibiting a CAGR of 5.6%. This growth is driven by rapid innovation, increasing investment, and shifting regional dynamics. The report provides key insights into market structure, segment trends, and strategic intelligence for decision-makers.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $520 | $505 | +3% |
| 2025-12-15 | Morgan Stanley | $425 | $425 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Outperform |
| 2025-12-15 | Morgan Stanley | down | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Heavy insider selling: $15M sold (4 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +1.8% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.25 suggests fair value with growth premium. Forward P/E 16.3x stretched relative to 7% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $113.2B |
| Beta | 1.37 |
| 52W Range | $295.00 - $520.00 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.25 |
| Forward P/E | 16.3 |
| Current P/E | 17.5 |
| YoY Growth | 7.3% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -0.3% to 1.5% (+1.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.5pp (needs >3.0% for momentum thesis). MRS_5 at 1.2% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.53% (CS: 53) | Neutral |
| RSI_14 | 55.8 | Neutral |
| MACD Histogram | 0.11 | Bullish |
| vs SMA20 | 1.017x | Above |
| vs SMA50 | 1.012x | Above |
| vs SMA200 | 1.199x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $483.57
- **Stop Loss:** $462.51 (4.4% risk)
- **Target:** $504.63 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 62
- **Position Value:** $29,981.34
- **Portfolio %:** 29.98%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*